FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 532 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Less Frequent Mammographic Surveillance Non-inferior Compared with Annual Mammograms After Diagnosis... February 18, 2025 Double Mastectomies Do Not Lower Risk Of Death For Breast Cancer... January 22, 2020 5-Yr-Old Cancer Survivor Used His Birthday To Collect Toys For Sick... October 15, 2019 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... Early cancer diagnosis and COVID-19: unpicking the impact of the pandemic Antibody Drug Ejects Problematic Proteins from Cancer Cells New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer...
